臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"liu c h"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 436-485 / 1570 (共32頁)
<< < 4 5 6 7 8 9 10 11 12 13 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2021-09-04T05:17:00Z	Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study	Liu C.-H.; Huang Y.-J.; Yang S.-S.; Chang C.-H.; Yang S.-S.; Sun H.-Y.; Liu C.-J.; Liu W.-C.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:59Z	Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan	Liu C.-H.; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:58Z	Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan	Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:57Z	Editorial: comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting anti-viral agents in chronic hepatitis C – authors’ reply	Liu C.-H.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:56Z	Editorial: nephrotoxicity and oral anti-viral therapy for HBV-facts or fiction?	Liu C.-H.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:55Z	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions	Yu M.-L.; Hung C.-H.; Huang Y.-H.; Peng C.-Y.; Lin C.-Y.; Cheng P.-N.; Chien R.-N.; Hsu S.-J.; Liu C.-H.; Huang C.-F.; Su C.-W.; Huang J.-F.; Liu C.-J.; JIA-HORNG KAO; Chuang W.-L.; Chen P.-J.; Chen D.-S.
臺大學術典藏	2021-09-04T05:16:55Z	Profile and value of FIB-4 in patients with dual chronic hepatitis C and B	Liu C.-J.; Tseng T.-C.; Yang W.-T.; Su T.-H.; Yang H.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:54Z	Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection	Su T.-H.; Liu C.-J.; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:53Z	Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma	Su T.-H.; Liu C.-J.; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:51Z	Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study	Liu C.-H.; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:50Z	Letter: contraindicated drug-drug interactions before and after initiation of direct-acting anti-viral agents in chronic hepatitis C patients in Taiwan. Authors’ reply	Liu C.-H.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:48Z	Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium	Huang C.-F.; Iio E.; Jun D.W.; Ogawa E.; Toyoda H.; Hsu Y.-C.; Haga H.; Iwane S.; Enomoto M.; Lee D.H.; Wong G.; Liu C.-H.; Tada T.; Chuang W.-L.; Cheung R.; Hayashi J.; Tseng C.-H.; Yasuda S.; Tran S.; Kam L.; Henry L.; Jeong J.Y.; Nomura H.; Park S.H.; Nakamuta M.; Huang J.-F.; Tai C.-M.; Lo G.-H.; Lee M.-H.; Yang H.-I.; JIA-HORNG KAO; Tamori A.; Eguchi Y.; Ueno Y.; Furusyo N.; Tanaka Y.; Yu M.-L.; Nguyen M.H.; For the REAL-C Investigators
臺大學術典藏	2021-09-04T05:16:48Z	Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection	Liu C.-H.; Su T.-H.; Liu C.-J.; Hong C.-M.; Yang H.-C.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:46Z	NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging	Su T.-H.; Liao S.-H.; Hong C.-M.; Liu C.-J.; Tseng T.-C.; Liu C.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chen C.-L.; Adhoute X.; Bourli?re M.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:46Z	Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis	Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; Su T.-H.; Liu C.-J.; Yang H.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:45Z	Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism	Su T.-H.; Yang H.-C.; Tseng T.-C.; Chou S.-W.; Lin C.-H.; Liu C.-H.; Liu C.-J.; Chen C.-L.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:45Z	High Level of Hepatitis B Core–Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load	Tseng T.-C.; Liu C.-J.; Hsu C.-Y.; Hong C.-M.; Su T.-H.; Yang W.-T.; Chen C.-L.; Yang H.-C.; Huang Y.-T.; Fang-Tzu Kuo S.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:42Z	Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment	Liu C.-H.; Chen C.-Y.; Su W.-W.; Tseng K.-C.; Lo C.-C.; Liu C.-J.; Chen J.-J.; Peng C.-Y.; Shih Y.-L.; Yang S.-S.; Huang C.-S.; Huang K.-J.; Chang C.-Y.; Tsai M.-C.; Kao W.-Y.; Fang Y.-J.; Chen P.-Y.; Su P.-Y.; Tseng C.-W.; Huang J.-J.; Lee P.-L.; Lai H.-C.; Hsieh T.-Y.; Chang C.-H.; Huang Y.-J.; Lee F.-J.; Chang C.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:41Z	Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis	Su T.-H.; Peng C.-Y.; Tseng T.-C.; Yang H.-C.; Liu C.-J.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:40Z	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan	Liu C.-H.; Liu C.-J.; Hung C.-C.; Hsieh S.-M.; Su T.-H.; Sun H.-Y.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:39Z	Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy	Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; Su T.-H.; Wang C.-C.; Liu C.-J.; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:38Z	Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals	Liu C.-H.; Lee M.-H.; Lin J.-W.; Liu C.-J.; Su T.-H.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:37Z	HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis	Tseng T.-C.; Liu C.-J.; Chang C.T.; Su T.-H.; Yang W.-T.; Tsai C.-H.; Chen C.-L.; Yang H.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:37Z	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment	Liu C.-H.; Yang S.-S.; Peng C.-Y.; Lin W.-T.; Liu C.-J.; Su T.-H.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:36Z	2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population	Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; Liu C.-J.; Peng C.-Y.; Lin H.-C.; JIA-HORNG KAO; Chuang W.-L.
臺大學術典藏	2021-09-04T05:16:34Z	2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations	Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; Liu C.-J.; Peng C.-Y.; Lin H.-C.; JIA-HORNG KAO; Chuang W.-L.
臺大學術典藏	2021-09-04T05:16:33Z	Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer	Su T.-H.; Tseng T.-C.; Liu C.-J.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chen C.-L.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:33Z	Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data	Hong C.-M.; Liu C.-H.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen Y.-W.; JIA-HORNG KAO; Liu C.-J.
臺大學術典藏	2021-09-04T05:16:31Z	Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)	Huang C.-F.; Lai H.-C.; Chen C.-Y.; Tseng K.-C.; Kuo H.-T.; Hung C.-H.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO; Liu C.-J.; Liu C.-H.; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Tsai P.-C.; Peng C.-Y.; Yu M.-L.
臺大學術典藏	2021-09-04T05:16:28Z	Successful antiviral therapy reduces risk of schizophrenia among chronic hepatitis c patients: A nationwide real-world Taiwanese cohort (T-COACH)	Tsai P.-C.; Chen C.-Y.; Kuo H.-T.; Hung C.-H.; Tseng K.-C.; Lai H.-C.; Peng C.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; JIA-HORNG KAO; Liu C.-J.; Liu C.-H.; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Tai C.-M.; Lin C.-W.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang C.-F.; Hsieh M.-H.; Huang J.-F.; Dai C.-Y.; Chung W.-L.; Ke C.-L.K.; Yu M.-L.; T-COACH Study Group
臺大學術典藏	2021-09-04T05:16:27Z	High risk of clinical relapse in patients with chronic Hepatitis B virus infection after cessation of prophylactic antiviral therapy for rituximab-containing chemotherapy	Chang W.-Y.; Chiu Y.-C.; Chiu F.-W.; Hsu Y.-C.; Tseng T.-C.; Cheng P.-N.; Yang S.-S.; Liu C.-J.; Su T.-H.; Yang H.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:26Z	Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis	Hsu W.-F.; Chen C.-Y.; Tseng K.-C.; Lai H.-C.; Kuo H.-T.; Hung C.-H.; Tung S.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Lin C.-Y.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO; Liu C.-J.; Liu C.-H.; Yan S.-L.; Bair M.-J.; Su W.-W.; Chu C.-H.; Chen C.-J.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Tsai P.-C.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Yu M.-L.; Peng C.-Y.
臺大學術典藏	2021-09-04T05:16:25Z	Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan	Liu C.-H.; Su T.-H.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:25Z	Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis	Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:24Z	Hepatitis C virus cure rates are reduced in patients with active but not inactive hepatocellular carcinoma: A practice implication	Ogawa E.; Toyoda H.; Iio E.; Jun D.W.; Huang C.-F.; Enomoto M.; Hsu Y.-C.; Haga H.; Iwane S.; Wong G.; Lee D.H.; Tada T.; Liu C.-H.; Chuang W.-L.; Hayashi J.; Cheung R.; Yasuda S.; Tseng C.-H.; Takahashi H.; Tran S.; Yeo Y.H.; Henry L.; Barnett S.D.; Nomura H.; Nakamuta M.; Dai C.-Y.; Huang J.-F.; Yang H.-I.; Lee M.-H.; Jun M.J.; JIA-HORNG KAO; Eguchi Y.; Ueno Y.; Tamori A.; Furusyo N.; Yu M.-L.; Tanaka Y.; Nguyen M.H.; Ahn S.B.; Azuma K.; Dohmen K.; Jeong J.Y.; Jung J.H.; Kajiwara E.; Kato M.; Kawano A.; Koyanagi T.; Ooho A.; Park S.H.; Satoh T.; Shimoda S.; Song D.S.; Takahashi K.; Yeh M.-L.; Yoon E.L.; Real-World Evidence from the Asia Liver Consortium Investigators
臺大學術典藏	2021-09-04T05:16:23Z	Reply to: “Sofosbuvir and the risk of kidney dysfunction”	Liu C.-H.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:21Z	Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis	Su T.-H.; Peng C.-Y.; Chang S.-H.; Tseng T.-C.; Liu C.-J.; Chen C.-L.; Liu C.-H.; Yang H.-C.; Chen P.-J.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:21Z	Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)	Yeh M.-L.; Hung C.-H.; Tseng K.-C.; Lai H.-C.; Chen C.-Y.; Kuo H.-T.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO; Liu C.-H.; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Huang C.-F.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Tsai P.-C.; Peng C.-Y.; Liu C.-J.; Yu M.-L.
臺大學術典藏	2021-09-04T05:16:18Z	Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load	Tseng T.-C.; Liu C.-J.; Yang W.-T.; Hsu C.-Y.; Hong C.-M.; Su T.-H.; Tsai C.-H.; Chen C.-L.; Yang H.-C.; Liu C.-H.; Chen H.-H.; Chen P.-J.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:17Z	Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan	Liu C.-H.; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; Liu C.-J.; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; Fang Y.-J.; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; Hung C.-C.; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.?Y.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:16Z	Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan	Chen C.-Y.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Lo C.-C.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; Liu C.-H.; Lee M.-H.; Liu C.-J.; Dai C.-Y.; JIA-HORNG KAO; Chuang W.-L.; Lin H.-C.; Yu M.-L.
臺大學術典藏	2021-09-02T02:29:15Z	De Novo synthesis of platinum-nanoparticle-encapsulated UiO-66-NH2 for photocatalytic thin film fabrication with enhanced performance of phenol degradation	Chen S.S;Hu C;Liu C.-H;Chen Y.-H;Ahamad T;Alshehri S.M;Huang P.-H;Wu K.C.-W.; Chen S.S; Hu C; Liu C.-H; Chen Y.-H; Ahamad T; Alshehri S.M; Huang P.-H; Wu K.C.-W.; KEVIN CHIA-WEN WU
臺大學術典藏	2021-09-02T02:29:12Z	Erratum: Biocompatible and multifunctional gold nanorods for effective photothermal therapy of oral squamous cell carcinoma (Journal of Materials Chemistry B (2019) 7 (4451–4460) DOI: 10.1039/C9TB00574A)	Liao Y.-T;Liu C.-H;Chin Y;Chen S.-Y;Liu S.H;Hsu Y.-C;Wu K.C.-W.; Liao Y.-T; Liu C.-H; Chin Y; Chen S.-Y; Liu S.H; Hsu Y.-C; Wu K.C.-W.; KEVIN CHIA-WEN WU
臺大學術典藏	2021-09-02T02:29:08Z	Oxidation of biomass-derived furans to maleic acid over nitrogen-doped carbon catalysts under acid-free conditions	Van Nguyen C;Boo J.R;Liu C.-H;Ahamad T;Alshehri S.M;Matsagar B.M;Wu K.C.-W.; Van Nguyen C; Boo J.R; Liu C.-H; Ahamad T; Alshehri S.M; Matsagar B.M; Wu K.C.-W.; KEVIN CHIA-WEN WU
臺大學術典藏	2021-09-02T00:04:05Z	Improved design and in vivo animal tests of bone-guided cochlear implant microsystem with monopolar biphasic multiple stimulation and neural action potential acquisition	Wang S.-H;Huang Y.-K;Chen C.-Y;Lee C.-F;Yang C.-H;Hung C.-C;Liu C.-H;Ker M.-D;Wu C.-Y.; Wang S.-H; Huang Y.-K; Chen C.-Y; Lee C.-F; Yang C.-H; Hung C.-C; Liu C.-H; Ker M.-D; Wu C.-Y.; CHIA-HSIANG YANG
臺大學術典藏	2021-09-01T02:02:52Z	Adult acute lymphoblastic leukemia--lineage specific classification of 30 cases.	ANN-LII CHENG; Chen Y.C.; Wang C.H.; Shen M.C.; Hsieh R.P.; Tien H.F.; Liu M.C.; Lai H.S.; Liu C.H.
臺大學術典藏	2021-09-01T02:02:51Z	Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades - Should peripheral T-cell lymphoma be considered separately?	ANN-LII CHENG; Chen Y.-C.; Wang C.-H.; Su I.-J.; Hsieh H.-C.; Chang J.-Y.; Hwang W.-S.; Su W.-C.; Liu T.-W.; Tien H.-F.; Tsai W.; Shen M.-C.; Liu C.-H.
臺大學術典藏	2021-09-01T02:02:51Z	Adult non-Hodgkin's lymphoma in Taiwan area: A clinicopathologic study of 123 cases based on working formulation classification	ANN-LII CHENG; Chen Y.-C.; Su I.-J.; Wang C.-H.; Hsieh H.-C.; Chen C.-L.; Lai H.-S.; Liu T.-W.; Tien H.-F.; Shen M.-C.; Liu C.-H.
臺大學術典藏	2021-09-01T02:02:50Z	Bone marrow involvement in non-Hodgkin's lymphoma.	Lai H.S.; Tien H.F.; Hsieh H.C.; Chen Y.C.; Su I.J.; Wang C.H.; Liu M.C.; ANN-LII CHENG; Shen M.C.; Liu C.H.
臺大學術典藏	2021-09-01T01:54:32Z	Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL	Lay J.-D.; Hong C.-C.; Huang J.-S.; Yang Y.-Y.; Pao C.-Y.; Liu C.-H.; Lai Y.-P.; Lai G.-M.; ANN-LII CHENG; Su I.-J.; Chuang S.-E.

顯示項目 436-485 / 1570 (共32頁)
<< < 4 5 6 7 8 9 10 11 12 13 > >>
每頁顯示[10|25|50]項目

	English \| 正體中文 \| 简体中文 \| 總筆數 :0
	造訪人次 : 51881520 線上人數 : 783 教育部委託研究計畫計畫執行:國立臺灣大學圖書館